While the ketogenic diet is widely acknowledged as an effective therapy for difficult-to-treat epilepsy, its use in clinical practice remains limited due to concerns such as poor patient compliance and potential side effects like acute pancreatitis, adverse effects on bone health, elevated monocyte counts, and reduced IgA concentrations [58–60]. The gene discussed is CD79A; the disease is epilepsy.